Key Highlights

  • Creo Medical Group Plc (LSE:CREO) gained 2.94% on 7 October 2026.
  • H1 2026 Revenue rose 45% to £3.2m, and FY26 revenue growth guidance is 50% to 60%.
  • Cash stood at £7.4m at the end of June 2026, supported by a £5.5m placing and a £2.0m convertible Loan note.
  • The sale of the remaining 49% interest in Creo Medical SL was expected to complete during the third quarter of 2026.

Why Is Creo Medical Group Plc (LSE:CREO) in Focus?

Creo Medical Group Plc (LSE:CREO), the medical device company focused on minimally invasive surgical endoscopy for pre-cancer and cancer patients, rose 2.94% on 7 October 2026. The company had said it expected the sale of its remaining 49% interest in Creo Medical SL to complete during the third quarter of 2026 and planned to publish interim results in September, keeping news flow in focus.

No new announcement for 7 October had been identified at the time of writing. The gain appears to reflect continued confidence in Creo's commercial momentum, its streamlined cost base and progress on Balance Sheet strengthening.

Key Reasons Behind the 7 October 2026 Gain

Several factors appear to underpin the 2.94% rise in Creo Medical Group Plc (LSE:CREO). First, revenue growth of 45% in the first half and guidance of 50% to 60% for the year demonstrate accelerating commercial traction. Second, the outsourcing of Manufacturing and other cost reductions have narrowed losses, improving the outlook for reaching profitability.

Third, the expected completion of the sale of the remaining 49% interest in Creo Medical SL during the third quarter of 2026 offers the prospect of additional non-dilutive funding, which reduces the risk of further Equity raises. Investors may be anticipating confirmation of completion and the proceeds.

Finally, the company's clinical milestones, including the first UK private hospital use of Speedboat and growing MicroBlate procedure numbers, support the view that adoption is broadening across hospitals and geographies.

Commercial Momentum Building

For the six months ended 30 June 2026, Creo reported revenue up 45% to £3.2 million, compared with £2.2 million a year earlier. First-quarter revenue had risen about 60%, at the upper end of management expectations. The company narrowed its FY26 revenue growth guidance to 50% to 60%.

Growth has been driven by customer adoption, higher procedure volumes and conversion of the commercial pipeline. Key milestones included the first UK private hospital use of Speedboat, presentations at Digestive Disease Week, novel procedures using SpydrBlade Flex and more than 50 clinical cases with MicroBlate Fine, alongside over 100 MicroBlate Flex procedures.

Leaner Operating Model

Creo completed the disposal and outsourcing of its manufacturing operations during the second quarter of 2026, which it expected to reduce annual operating costs by more than £1.0 million. Underlying operating costs and the underlying operating loss both fell in the first half, reflecting restructuring initiatives.

For Creo Medical Group Plc (LSE:CREO), lower fixed costs combined with rising revenue improve Operating Leverage and support the stated path to profitability.

Funding and the CME Disposal

In May 2026 Creo completed an equity placing raising about £5.5 million and established a £2.0 million convertible loan note subscribed by the Development Bank of Wales. Cash was £7.4 million at the end of June 2026. The proposed sale of the remaining 49% interest in Creo Medical SL follows the sale of an initial 51% to Micro-Tech in early 2025, which generated net proceeds of about €30 million at an implied valuation of €72 million.

Completion of the 49% disposal would provide further non-dilutive funding.

Index and Market Context

Creo Medical is quoted on AIM and forms part of the FTSE AIM All-Share index. The shares trade at a low price in pence, and sentiment has improved during 2026 as revenue growth has accelerated.

What Investors Are Watching

Key watch points include completion and proceeds of the CME disposal, interim results detail, second-half revenue given the typically H2-weighted profile, new hospital sites, US commercial progress and reimbursement developments.

Risks to Consider

Risks include slower adoption, reimbursement and regulatory hurdles, funding requirements, competition and execution of outsourced manufacturing.

Conclusion

Creo Medical Group Plc (LSE:CREO) rose 2.94% on 7 October 2026 as investors weighed 45% revenue growth, a leaner cost base and the expected CME stake sale. Sustained adoption of Speedboat and MicroBlate will be central to its route to profitability.